Japanese @ Weblate

	Project	Translated	Unfinished	Unfinished words	Unfinished characters	Untranslated	Checks	Suggestions	Comments
	MtF.wiki	50%	129	10,309	25,565	129	0	0	0

Overview

Plural: Default plural 9 translations
Language code	ja
Aliased language codes	ja_ja, ja_jp, jp, jp_jpn, jpn, jpn_jp
Text direction	Left to right
Number of speakers	117,558,321
Number of plurals	1
Plural type	None
Plurals
Plural formula	`0`
Plural: Qt Linguist plural 0 translations
Number of plurals	1
Plural type	None
Plurals
Plural formula	`0`

yesterday

String statistics

	Strings percent	Hosted strings	Words percent	Hosted words	Characters percent	Hosted characters
Total		262		20,654		52,534
Approved	50%	133	50%	10,345	51%	26,969
Waiting for review	0%	0	0%	0	0%	0
Translated	50%	133	50%	10,345	51%	26,969
Needs editing	0%	0	0%	0	0%	0
Read-only	0%	0	0%	0	0%	0
Failing checks	0%	0	0%	0	0%	0
Strings with suggestions	0%	0	0%	0	0%	0
Untranslated strings	49%	129	49%	10,309	48%	25,565

Last 12 months Previous

Activity in last 12 months


Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb

Quick numbers

20,654

Hosted words

262

Hosted strings

50%

Translated

Contributors

and previous 30 days

Trends of last 30 days

−1%

Hosted words

+100%

−1%

Hosted strings

+100%

−1%

Translated

+52%

—

Contributors

—

None Resource updated MtF.wiki docs/medicine/hrt-overview Japanese	The “`content/ja/docs/medicine/hrt-overview.md`” file was changed. 3 days ago
None String added in the repository MtF.wiki docs/medicine/hrt-overview Japanese	Chinese (Simplified Han script) [^1]: Thompson J, Hopwood R A, de Normand S, et al. Medical Care of Trans and Gender Diverse Adults [EB/OL]. Fenway Health, (2021-07-13). <https://www.lgbtqiahealtheducation.org/publication/medical-care-of-trans-and-gender-diverse-adults-2021/> [^2]: Weinand J D, Safer J D. Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals [J]. Journal of Clinical & Translational Endocrinology, 2015, 2(2): 55-60. <https://doi.org/10.1016/j.jcte.2015.02.003> [^3]: Stricker R, Eberhart R, Chevailler M, et al. Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT® analyzer [J]. Clinical Chemistry and Laboratory Medicine, 2006, 44(7): 883–887. <https://doi.org/10.1515/CCLM.2006.160> [^4]: Coleman E, Radix A E, Bouman W P, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8 [J]. International Journal of Transgender Health, 2022, 23(Suppl 1): S1–S259. <https://doi.org/10.1080/26895269.2022.2100644> [^5]: Aly. An Introduction to Hormone Therapy for Transfeminine People [EB/OL]. Transfeminine Science, 2018. <https://transfemscience.org/articles/transfem-intro/> 【[译文](https://tfsci.mtf.wiki/zh-cn/articles/transfem-intro/)】 [^6]: Esoterix/LabCorp. Endocrinology Expected Values and S.I. Unit Conversion Tables [EB/OL]. 2020. \[[PDF 文档](https://specialtytesting.labcorp.com/sites/default/files/2021-07/L5167-0421-18%20Endocrine%20Expected%20Values_0.pdf)] [^7]: Aly. Approximate Comparable Dosages of Estradiol by Different Routes [EB/OL]. Transfeminine Science, 2020. <https://transfemscience.org/articles/e2-equivalent-doses/> 【[译文](https://tfsci.mtf.wiki/articles/e2-equivalent-doses/)】 [^8]: Jorgensen S C J. Transition Regret and Detransition: Meanings and Uncertainties [J]. Archives of Sexual Behavior, 2023, 52(5): 2173–2184. <https://doi.org/10.1007/s10508-023-02626-2> [^9]: Aly. An Informal Meta-Analysis of Estradiol Curves with Injectable Estradiol Preparations [EB/OL]. Transfeminine Science, 2021. <https://transfemscience.org/articles/injectable-e2-meta-analysis/> 【[译文](https://tfsci.mtf.wiki/zh-cn/articles/injectable-e2-meta-analysis/)】 [^10]: Aly. Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy [EB/OL]. Transfeminine Science, 2020. <https://transfemscience.org/articles/bica-adoption/> 【[译文](https://tfsci.mtf.wiki/zh-cn/articles/bica-adoption/)】 [^11]: REX Medical Ltd. New Zealand Datasheet: SITERONE [EB/OL]. Medsafe, (2020-03-30). <https://www.medsafe.govt.nz/profs/datasheet/s/Siteronetab.pdf> 【[译文](https://tfsci.mtf.wiki/zh-cn/misc/siterone-nz/)】 [^12]: Ainsworth A J, Allyse M, Khan Z. Fertility Preservation for Transgender Individuals: A Review [J]. Mayo Clinic Proceedings, 2020, 95(4): 784-792. <https://doi.org/10.1016/j.mayocp.2019.10.040> [^13]: Adeleye A J, Reid G, Kao C N, et al. Semen Parameters Among Transgender Women With a History of Hormonal Treatment [J]. Urology, 2019, 124: 136-141. <https://doi.org/10.1016/j.urology.2018.10.005> [^14]: Aly. Estrogens and Their Influences on Coagulation and Risk of Blood Clots [EB/OL]. Transfeminine Science, 2020. <https://transfemscience.org/articles/estrogens-blood-clots/> 【[译文](https://tfsci.mtf.wiki/zh-cn/articles/estrogens-blood-clots/)】 [^15]: Nolan B J, & Cheung A S. Relationship Between Serum Estradiol Concentrations and Clinical Outcomes in Transgender Individuals Undergoing Feminizing Hormone Therapy: A Narrative Review [J]. Transgender Health, 2021, 6(3): 125–131. <https://doi.org/10.1089/trgh.2020.0077> [^16]: Novartis. ESTRADERM® Prescribing Information & Patient Information [EB/OL]. Drugs@FDA, 2017. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019081s042lbl.pdf> 【[译文](https://tfsci.mtf.wiki/zh-cn/misc/estraderm/)】 [^17]: Aly. Breast Cancer Risk with Hormone Therapy in Transfeminine People [EB/OL]. Transfeminine Science, 2020. <https://transfemscience.org/articles/breast-cancer/> 【[译文](https://tfsci.mtf.wiki/zh-cn/articles/breast-cancer/)】 [^18]: Cox L R, Crawford D E. Estrogens in the Treatment of Prostate Cancer [J]. The Journal of Urology, 1995, 154(6): 1991-1998. <https://doi.org/10.1016/S0022-5347(01)66670-9> [^19]: Nishiyama T. Serum testosterone levels after medical or surgical androgen deprivation: A comprehensive review of the literature [J]. Urologic Oncology: Seminars and Original Investigations, 2014, 32(1): 38.e17-38.e28. <https://doi.org/10.1016/j.urolonc.2013.03.007> [^20]: Mitzi. Puberty Blockers: A Review of GnRH Analogues in Transgender Youth [EB/OL]. Transfeminine Science, 2022. <https://transfemscience.org/articles/puberty-blockers/> 【[译文](https://tfsci.mtf.wiki/zh-cn/articles/puberty-blockers/)】 [^21]: Aly. A Review of Studies on Spironolactone and Testosterone Suppression in Cisgender Men, Cisgender Women, and Transfeminine People [EB/OL]. Transfeminine Science, 2018. <https://transfemscience.org/articles/spiro-testosterone/> 【[译文](https://tfsci.mtf.wiki/zh-cn/articles/spiro-testosterone/)】 [^22]: Aly. Low Doses of Cyproterone Acetate Are Maximally Effective for Testosterone Suppression in Transfeminine People [EB/OL]. Transfeminine Science, 2019. <https://transfemscience.org/articles/cpa-dosage/> 【[译文](https://tfsci.mtf.wiki/zh-cn/articles/cpa-dosage/)】 [^23]: Aly. A Comprehensive Review of the Potential of Progestogens for Enhancing Breast Development in Transfeminine People [EB/OL]. Transfeminine Science, 2020. <https://transfemscience.org/articles/progestogens-breast-dev/> 【[译文](https://tfsci.mtf.wiki/zh-cn/articles/progestogens-breast-dev/)】 [^24]: Aly. Recent Developments on Cyproterone Acetate and Meningioma Risk Out of France and Implications for Transfeminine People [EB/OL]. Transfeminine Science, 2020. <https://transfemscience.org/articles/cpa-meningioma/> 【[译文](https://tfsci.mtf.wiki/zh-cn/articles/cpa-meningioma/)】 [^25]: Bahr C, Ewald J, Dragovich R, et al. Effects of progesterone on gender affirmation outcomes as part of feminizing hormone therapy [J]. Journal of the American Pharmacists Association, 2024, 64(1): 268-272. <https://doi.org/10.1016/j.japh.2023.08.001> [^26]: Sam. An Exploration of Sublingual Estradiol as an Alternative to Oral Estradiol in Transfeminine People [EB/OL]. Transfeminine Science, 2021. <https://transfemscience.org/articles/sublingual-e2-transfem/> 【[译文](https://tfsci.mtf.wiki/zh-cn/articles/sublingual-e2-transfem/)】 [^27]: Rueda C, Osorio A M, Avellaneda A C, et al. The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review [J]. Climacteric, 2017, 20(4): 321–330. <https://doi.org/10.1080/13697137.2017.1329291> [^28]: Takahashi K, Manabe A, Okada M, et al. Efficacy and safety of oral estriol for managing postmenopausal symptoms [J]. Maturitas, 2000, 34(2): 169-177. <https://doi.org/10.1016/S0378-5122(99)00108-5> [^29]: Holtorf K. The Bioidentical Hormone Debate: Are Bioidentical Hormones (Estradiol, Estriol, and Progesterone) Safer or More Efficacious than Commonly Used Synthetic Versions in Hormone Replacement Therapy? [J]. Postgraduate Medicine, 2009, 121(1): 73–85. <https://doi.org/10.3810/pgm.2009.01.1949> [^30]: Stege R, Gunnarsson P O, Johansson C, et al. Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin®) in prostatic cancer patients [J]. The Prostate, 1996, 28(5): 307–310. <https://doi.org/10.1002/(SICI)1097-0045(199605)28%3A5%3C307%3A%3AAID-PROS6%3E3.0.CO%3B2-8> [^31]: Aly. Oral Progesterone Achieves Very Low Levels of Progesterone and Has Only Weak Progestogenic Effects [EB/OL]. Transfeminine Science, 2018. <https://transfemscience.org/articles/oral-p4-low-levels/> 【[译文](https://tfsci.mtf.wiki/zh-cn/articles/oral-p4-low-levels/)】 [^32]: Kuhl H, Schneider H P G. Progesterone – promoter or inhibitor of breast cancer [J]. Climacteric, 2013, 16(Suppl 1): 54–68. <https://doi.org/10.3109/13697137.2013.768806> [^33]: Zitzmann M, Rohayem J, Raidt J, et al. Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial [J]. Andrology, 2017, 5(3): 516–526. <https://doi.org/10.1111/andr.12328> [^34]: Fung R, Hellstern-Layefsky M, Lega I. Is a lower dose of cyproterone acetate as effective at testosterone suppression in transgender women as higher doses? [J]. International Journal of Transgenderism, 2017, 18(2): 123–128. <https://doi.org/10.1080/15532739.2017.1290566> [^35]: Irwig M S. Is there a role for 5α‐reductase inhibitors in transgender individuals? [J]. Andrology, 2021, 9(6): 1729–1731. <https://doi.org/10.1111/andr.12881> [^36]: Yang W, Hong T, Chang X, et al. The efficacy of and user satisfaction with different antiandrogens in Chinese transgender women [J]. International Journal of Transgender Health, 2024, 25(3): 471–482. <https://doi.org/10.1080/26895269.2024.2323514> [^37]: Angus L M, Nolan B J, Zajac J D, et al. A systematic review of antiandrogens and feminization in transgender women [J]. Clinical Endocrinology, 2021, 94(5): 743–752. <https://doi.org/10.1111/cen.14329> [^38]: AstraZeneca. CASODEX® Prescribing Information [EB/OL]. Drugs@FDA, 2017. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf> 【[译文](https://tfsci.mtf.wiki/zh-cn/misc/casodex/)】 [^39]: Neyman A, Fuqua J S, Eugster E A. Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents [J]. Journal of Adolescent Health, 2019, 64(4): 544-546. <https://doi.org/10.1016/j.jadohealth.2018.10.296> [^40]: Pfizer. Prescribing Information: ALDACTONE® [EB/OL]. Drugs@FDA, 2022. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/012151s079lbl.pdf> 【[译文](https://tfsci.mtf.wiki/zh-cn/misc/aldactone/)】 [^41]: Aly. Clinical Guidelines with Information on Transfeminine Hormone Therapy [EB/OL]. Transfeminine Science, 2020. <https://transfemscience.org/articles/transfem-hormone-guidelines/> 【[译文](https://tfsci.mtf.wiki/zh-cn/articles/transfem-hormone-guidelines/)】 [^42]: Aly. An Exploration of Possibilities for Hormone Therapy in Non-Binary Transfeminine People [EB/OL]. Transfeminine Science, 2019. <https://transfemscience.org/articles/nonbinary-transfem-overview/> 【[译文](https://tfsci.mtf.wiki/zh-cn/articles/nonbinary-transfem-overview/)】 [^43]: van Leerdam T R, Zajac J D, Cheung A S. The Effect of Gender-Affirming Hormones on Gender Dysphoria, Quality of Life, and Psychological Functioning in Transgender Individuals: A Systematic Review [J]. Transgender Health, 2023, 8(1): 6-21. <https://doi.org/10.1089/trgh.2020.0094> [^44]: Eli Lilly and Company. EVISTA® Prescribing Information [EB/OL]. Drugs@FDA, 2018. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020815s034lbl.pdf> 【[译文](https://tfsci.mtf.wiki/zh-cn/misc/evista/)】 [^45]: Rost A, Schmidt-Gollwitzer M, Hantelmann W, et al. Cyproterone acetate, testosterone, LH, FSH, and prolactin levels in plasma after intramuscular application of cyproterone acetate in patients with prostatic cancer [J]. The Prostate, 1981, 2(3): 315-322. <https://doi.org/10.1002/pros.2990020310> Japanese 0 characters edited Current translation Empty 3 days ago
None String added in the repository MtF.wiki docs/medicine/hrt-overview Japanese	Chinese (Simplified Han script) - [醋酸环丙孕酮]({{< ref "cyproterone" >}})（CPA，也称“色普龙”） - [醋酸甲羟孕酮]({{< ref "medroxyprogesterone" >}})（MPA） - [GnRH 类似物]({{< ref "#puberty-blockers" >}})，一般用于青春期阻断，详见下文 - 高剂量雌激素单药治疗，如[注射]({{< ref "injection" >}})，一般无需再加用其它抗雄药物 + 以上可减少雄激素合成、降低雄激素水平。睾酮检查报告可直观反映其效果。注意在用药初期，睾酮下降需要数日方可完成[^45]，不宜操之过急。 - [螺内酯]({{< ref "spironolactone" >}}) {{< tag/neg "略不推荐" >}} - [比卡鲁胺]({{< ref "bicalutamide" >}}) {{< tag/neg "不推荐常规应用" >}} + 以上可作用于雄激素受体，直接阻断雄激素活动。睾酮检查报告不能反映此类药物的效果。 Japanese 0 characters edited Current translation Empty 3 days ago
None String added in the repository MtF.wiki docs/medicine/hrt-overview Japanese	Chinese (Simplified Han script) 可以看到，当雌二醇水平上升到并维持于 200 pg/mL 以上时，睾酮水平被抑制到顺性别女性参考范围内（55 ng/mL 以下）。而从上表可以得知，无论何种途径都需要很高剂量来达到 200 pg/mL 的目标[^7]；除注射剂以外，不仅成本飙升，使用上的不便也会越发显著。因此我们仅推荐将针剂用于雌二醇单药治疗。 Japanese 0 characters edited Current translation Empty 3 days ago
None String added in the repository MtF.wiki docs/medicine/hrt-overview Japanese	Chinese (Simplified Han script) \| 参考指标 \| ng/mL \| nmol/L \| \|-\|-\|-\| \| 睾酮（绝经前女性） \| 0.10 – 0.55 \| 0.35 – 1.91 \| \| 睾酮（男性） \| 2.64 – 9.16 \| 9.15 – 31.76 \| \| 泌乳素（女性） \| 4.79 – 23.3 \| \| Japanese 0 characters edited Current translation Empty 3 days ago
None String added in the repository MtF.wiki docs/medicine/hrt-overview Japanese	Chinese (Simplified Han script) 检查结果该怎么看呢？重点观察雌二醇和睾酮；建议观察泌乳素（PRL），发现升高时密切随访，详情在[这里]({{< ref "monitoring" >}})可见；LH、FSH 仅建议在青春期阻断治疗期间观察；孕酮基本没有参考意义。下面是成年女性及男性的雌二醇和睾酮水平参考范围[^6]： Japanese 0 characters edited Current translation Empty 3 days ago
None Resource updated MtF.wiki docs/medicine/hrt-overview Japanese	The “`content/ja/docs/medicine/hrt-overview.md`” file was changed. 2 weeks ago
None String added in the repository MtF.wiki docs/medicine/hrt-overview Japanese	Chinese (Simplified Han script) - 2022 年 11 月 30 日，国家药监局发布《[药品网络销售禁止清单（第一版）](https://link.mtf.wiki/prohibited-drugs/1)》，其中将环丙孕酮和雌二醇列为“用药风险较高的品种”和“其他禁止通过网络零售的药品”[^98]。 - 2023 年 7 月 10 日，国家药监局综合司在《[关于「药品网络销售禁止清单（第一版）」有关问题的复函](https://project-trans.org/china-legal/spec/2023-07-10/fgwj-2023-10001)》中强调禁止含雌二醇单方的复合包装产品经网络销售[^99]。所涉产品含“克龄蒙”。 Japanese 0 characters edited Current translation Empty 2 weeks ago
None Resource updated MtF.wiki docs/hrt/_index Japanese	The “`content/ja/docs/hrt/_index.md`” file was changed. 3 weeks ago
None Resource updated MtF.wiki docs/medicine/monitoring Japanese	Parsing of the “`content/ja/docs/medicine/monitoring.md`” file was enforced. 2 months ago

Browse all changes for this language

Search

Advanced query builder

Query examples

Review strings changed by other users	`changed:>="1 month ago" AND NOT changed_by:anonymous`	Add
Translated strings	`state:>=translated`	Add
Strings with comments	`has:comment`	Add
Strings with any failing checks	`has:check`	Add
Strings with suggestions from others	`has:suggestion AND NOT suggestion_author:anonymous`	Add
Approved strings with suggestions	`state:approved AND has:suggestion`	Add
All untranslated strings added the past month	`added:>="1 month ago" AND state:<=needs-editing`	Add
Strings changed in the past two weeks	`changed:>="2 weeks ago"`	Add

Shortcut	Action
`?`	Open available keyboard shortcuts.
`Alt` + `Home`	Navigate to the first translation in the current search.
`Alt` + `End`	Navigate to the last translation in the current search.
`Alt` + `PageUp` or `Ctrl` + `↑` or `Alt` + `↑` or `Cmd` + `↑` or	Navigate to the last translation in the current search.
`Alt` + `PageDown` or `Ctrl` + `↓` or `Alt` + `↓` or `Cmd` + `↓` or	Navigate to the next translation in the current search.
`Ctrl` + `Enter` or `Cmd` + `Enter`	Submit current form; this works the same as pressing Save and continue while editing translation.
`Ctrl` + `Shift` + `Enter` or `Cmd` + `Shift` +`Enter`	Unmark translation as Needing edit and submit it.
`Alt` + `Enter` or `Option` + `Enter`	Submit the string as a suggestion; this works the same as pressing Suggest while editing translation.
`Ctrl` + `E` or `Cmd` + `E`	Focus on translation editor.
`Ctrl` + `U` or `Cmd` + `U`	Focus on comment editor.
`Ctrl` + `M` or `Cmd` + `M`	Shows Automatic suggestions tab.
`Ctrl` + `1` to `Ctrl` + `9` or `Cmd` + `1` to `Cmd` + `9`	Copies placeable of a given number from source string.
`Ctrl` + `M` followed by `1` to `9` or `Cmd` + `M` followed by `1` to `9`	Copy the machine translation of a given number to current translation.
`Ctrl` + `I` followed by `1` to `9` or `Cmd` + `I` followed by `1` to `9`	Ignore one item in the list of failing checks.
`Ctrl` + `J` or `Cmd` + `J`	Shows the Nearby strings tab.
`Ctrl` + `S` or `Cmd` + `S`	Focus on search field.
`Ctrl` + `O` or `Cmd` + `O`	Copy the source string.
`Ctrl` + `Y` or `Cmd` + `Y`	Toggle the Needs editing checkbox.
`→`	Browse the next translation string.
`←`	Browse the previous translation string.